The Physiological Role of the Hormone Adropin And Its Relationship to Oxidative Stress In Patients With Degenerative Arthritis

Abstract

This study examined adropin, oxidative stress, and antioxidants in osteoarthritis patients and a control group, as well as the relationship between adropin and these factors. To achieve this goal, we collected 150 samples from 30–65-year-old men and women. Osteoarthritis affected 92 people. Patients were classified by disease severity: mild, moderate, or severe. The control group of 58 people is used for comparison. Quantified were adropin, glutathione (GSH), uric acid (UA), and MDA. Results show significant Adropin reduction (p≤0.0001) in osteoarthritis patients (282 ± 158.6 ng/L) compared to the control group (433.5 ± 119.7 ng/L). Adropin significantly reduced severe osteoarthritis (111±24.8 ng/L) compared to moderate (336.3±99.1 ng/L) and mild (410.3±108.4 ng/L) instances compared to the control group (p≤0.0001). Adropin and GSH are positively correlated in severe (r=0.446, p=0.004) and moderate (r=0.519, p=0.0013) cases. Adropin is negatively correlated with MDA in mild (r=-0.493, p=0.031) and severe (r=-0.542, p=0.001) instances. Adropin negatively correlates with uric acid in moderate (r=-0.525, p=0.012) and severe (r=-0.467, p=0.002) cases. This study supports the use of adropin to diagnose and track osteoarthritis. We also find a link between adropin and oxidative stress, suggesting it contributes to disease progression.